Pacira BioSciences (PCRX) Interest & Investment Income (2010 - 2026)

Pacira BioSciences' Interest & Investment Income history runs 17 years deep, the most recent figure standing at $1.9 million for Q1 2026.

• On a quarterly basis, Interest & Investment Income fell 72.01% year-over-year to $1.9 million in Q1 2026; TTM through Mar 2026 was $17.8 million, a 21.67% decrease from a year earlier, with the FY2025 full-year figure at $22.7 million, up 15.46% from the prior year.
• Interest & Investment Income retreated to $1.9 million in Q1 2026 per PCRX's latest filing, from $2.3 million in the prior quarter.
• Across five years, Interest & Investment Income topped out at $8.5 million in Q3 2025 and bottomed at $252000.0 in Q2 2022.
• The 5-year median for Interest & Investment Income is $3.1 million (2023), against an average of $3.5 million.
• Across the five-year window, Interest & Investment Income surged 3381.25% in 2022 and plunged 72.01% in 2026, its largest moves.
• Year by year, Interest & Investment Income stood at $2.8 million in 2022, then gained by 22.98% to $3.4 million in 2023, then jumped by 62.19% to $5.6 million in 2024, then slumped by 58.69% to $2.3 million in 2025, then dropped by 15.9% to $1.9 million in 2026.
• Per Business Quant, the three latest PCRX Interest & Investment Income figures stand at $1.9 million (Q1 2026), $2.3 million (Q4 2025), and $8.5 million (Q3 2025).